Skip to main content
. 2022 Jul 2;11:132–145. doi: 10.1016/j.xjon.2022.06.019

Figure 3.

Figure 3

Between March 2017 and November 2019, 7 patients with refractory cardiogenic shock cannulated on venoarterial extracorporeal membranous oxygenation (VA-ECMO) were bridged to cardiac transplant. Six patients with refractory cardiogenic shock were cannulated on VA-ECMO and bridged to left ventricular assist device placement (LVAD) with a HeartMate 3 (HM3) device. Markov modeling was used to estimate the incremental cost-effectiveness of bridging patients with cardiogenic shock to transplant or LVAD placement. In both scenarios, bridging patients with VA-ECMO who are in refractory cardiogenic shock to transplant or LVAD placement was not cost effective, with cost effective estimates above the willingness to pay willingness-to-pay (WTP) threshold of $50,000. ICER, Incremental cost-effectiveness ratio.